Nobilis Therapeutics Announces IND Filing for a Phase IIb Clinical Trial of NBTX-001 Drug/Device Combination for Treatment of Posttraumatic Stress Disorder
Nobilis Therapeutics, a biopharmaceutical company focused on the advancement of innovative CNS therapies, today announced that it has filed an Investigational New Drug application (IND) with the U.S. Food & Drug Administration (FDA) to initiate a Phase IIb clinical trial…
Nobilis Therapeutics Enters Into Collaboration With The Linde Group to Support Its Clinical Research Program to Study a Drug/Device Combination for Treatment of PTSD and Other CNS Disorders
Nobilis Therapeutics, a biopharmaceutical company focused on the advancement of innovative Central Nervous System therapies based on the use of noble gas mixtures, today announced that it has entered into a collaboration with The Linde Group to support its ongoing…
US Patent Granted for Nobilis Therapeutics Invention Covering Treatments of Rheumatologic Disorders With Noble Gases
Nobilis Therapeutics announced today the issuance of the United States patent filed by the company in June of 2017. The patent number 10,022,397, titled “TREATMENT OF RHEUMATOID ARTHRITIS USING NOBLE GAS MIXTURES” covers a wide range of noble gas uses…